GeneDx Holdings Corp. (WGS)
| Market Cap | 2.56B -31.0% |
| Revenue (ttm) | 454.43M +25.4% |
| Net Income | -106.36M |
| EPS | -3.64 |
| Shares Out | 29.82M |
| PE Ratio | n/a |
| Forward PE | 126.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,208 |
| Open | 83.85 |
| Previous Close | 86.48 |
| Day's Range | 82.00 - 87.13 |
| 52-Week Range | 32.21 - 170.87 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 90.44 (+5.22%) |
| Earnings Date | Oct 27, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Financial Performance
In 2025, GeneDx Holdings's revenue was $427.54 million, an increase of 39.97% compared to the previous year's $305.45 million. Losses were -$21.02 million, -59.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $90.44, which is an increase of 5.22% from the latest price.
News
GeneDx, Beren Therapeutics launch NPC GenomeComplete
GeneDx (WGS) announced a collaboration with Beren Therapeutics to launch the NPC GenomeComplete Sponsored Testing Program. The program provides no-cost genome sequencing for eligible pediatric patient...
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Strong Q2 growth was driven by core channels, with significant untapped potential remaining in geneticists, pediatric neurology, and NICU. Expansion into primary care and prenatal markets is underway, supported by new guidelines and operational improvements. Collection rates and gross margins are expected to rise as automation and payer-specific processes are implemented.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx announces data published in Genetics in Medicine on genome sequencing
GeneDx (WGS) announced new data published in Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics, ACMG, in collaboration with the clinical genetics team…
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
Second quarter saw 32% volume growth and a return to adjusted profitability, driven by expanded policy coverage for whole genome sequencing. Efforts focus on improving collection rates, optimizing product mix, and leveraging new guidelines and commercial expansion to drive future revenue growth.
GeneDx launches new online offering to expand accessibility of exome testing
GeneDx (WGS) announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay, GDD,…
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
GeneDx price target raised to $90 from $75 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on GeneDx (WGS) to $90 from $75 and keeps a Buy rating on the shares. The firm said its target increase…
GeneDx Holdings Earnings Call Transcript: Q2 2026
Record Q2 volume and revenue exceeded guidance, with profitability achieved ahead of schedule. Strong demand and expanded payer coverage, especially for genome testing, set the stage for sustained growth, with significant improvements in collection rates and cash flow expected in late 2026 and 2027.
GeneDx Holdings Slides: Q2 2026
GeneDx Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
GeneDx Holdings Earnings release: Q2 2026
GeneDx Holdings released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
GeneDx Holdings Quarterly report: Q2 2026
GeneDx Holdings has published its Q2 2026 quarterly earnings report on August 3, 2026.
GeneDx Reports Second Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
Key Dates and Disclosure Events GeneDx Shareholders Need to Know: From $51 Million Acquisition Promise to $31.2 Million Write-Off in Just 12 Months NEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt al...
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026.
GeneDx price target raised to $85 from $55 at TD Cowen
TD Cowen raised the firm’s price target on GeneDx (WGS) to $85 from $55 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group…
WGS Stockholders Have Rights – If You Lost Money Investing in GeneDx Holdings Corp. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is Investigating Allegations that GeneDx Holdings Corp. (WGS) Misled Investors Regarding the Positive Impact of the Fabric Genomics Acquisiti
GeneDx price target raised to $74 from $70 at Guggenheim
Guggenheim raised the firm’s price target on GeneDx (WGS) to $74 from $70 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
GeneDx price target raised to $63 from $50 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on GeneDx (WGS) to $63 from $50 and keeps an Overweight rating on the shares. Carelon’s new outpatient genome coverage…
GeneDx Holdings Transcript: AGM 2026
The meeting highlighted strong financial growth, FDA recognition, and strategic expansion into new markets. All four shareholder proposals passed with significant majorities, and no questions were raised during the Q&A session.
GeneDx appoints Gardner as President
GeneDx (WGS) announced the appointment of Mark Gardner as President, effective June 15, 2026. Reporting to Katherine Stueland, Chief Executive Officer, Gardner will lead GeneDx’s commercial and operat...
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.